BLA 761291 · Janssen Biotech
Tecvayli
Teclistamab-Cqyv · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Oct 25, 2022: To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Oct 25, 2022
Approved uses
4
Original approval plus efficacy supplements
Registered trials
63
13 Phase 3, 32 recruiting
FAERS reports
2,379
1,947 serious, 444 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.5) and Warnings and Precautions (5.1) ] . Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious, life-threatening, or fatal reactions, can occur in patients receiving TECVAYLI. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI until neurologic toxicity resolves or permanently discontinue based on severity [see Dosage and...
What it is approved for
From the label in effect Mar 10, 2026.
TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma: in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent ( 1 ). as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody ( 1 ).
Mechanism: Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro , teclistamab-cqyv activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 5, 2026 Supplement 18 · Efficacy · priority review Breakthrough therapyOrphanLetterLabelMedication Guide
- Nov 22, 2024 Supplement 9 · Efficacy OrphanLetter
- Feb 20, 2024 Supplement 3 · Efficacy OrphanLetterLabel
- Oct 25, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- TECVAYLI · TECLISTAMAB-CQYV 30MG/3ML(10MG/ML) · INJECTABLE, INJECTION · Prescription
- TECVAYLI · TECLISTAMAB-CQYV 153MG/1.7ML(90MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Teclistamab" as an intervention, any sponsor and status, largest first.
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationPivotal-lookingActive, not recruiting
European Myeloma Network B.V.Research network
NCT05243797 · 1,594 participants (planned) · Start Sep 8, 2022 · Primary completion Apr 2028
Drug: Teclistamab; Lenalidomide · For: Multiple Myeloma
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 201 sites in all
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelPivotal-lookingRecruiting
University of LeedsAcademic, hospital or other
NCT07649525 · 1,226 participants (planned) · Start Jul 3, 2026 · Primary completion Jun 2033
Drug: Daratumumab; Lenalidomide and 3 more · For: Multiple Myeloma (MM); Plasma Cell Leukemia (PCL)
Sites: Bristol, United Kingdom; Eastbourne, United Kingdom; Leeds, United Kingdom · 5 sites in all
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaPivotal-lookingNot yet recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07887984 · 920 participants (planned) · Start Dec 23, 2026 · Primary completion Aug 1, 2033
Drug: Daratumumab and Recombinant Human Hyaluronidase; Lenalidomide and 5 more · For: Multiple Myeloma (MM)
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomidePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06208150 · 838 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Talquetamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Clovis, California; Santa Monica, California; New Haven, Connecticut · 242 sites in all
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07518186 · 700 participants (planned) · Start May 31, 2026 · Primary completion Apr 29, 2029
Drug: JNJ-79635322; Teclistamab · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Springdale, Arkansas · 173 sites in all
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05572515 · 614 participants · Start Mar 29, 2023 · Primary completion Oct 13, 2025
Drug: Teclistamab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Anchorage, Alaska; Gilbert, Arizona; Berkeley, California · 211 sites in all
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05083169 · 587 participants · Start Oct 14, 2021 · Primary completion Aug 1, 2025
Drug: Daratumumab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Duarte, California; Stanford, California · 176 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome582
- immune effector cell-associated neurotoxicity syndrome211
- off label use199
- death155
- infection136
- plasma cell myeloma131
- neutropenia116
- fatigue99
- pyrexia94
- pneumonia92
- covid-1988
- drug ineffective73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 11 |
| 2023 | 408 |
| 2024 | 616 |
| 2025 | 772 |
| 2026 | 572 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tecvayli (Teclistamab-Cqyv)
2024 spending
$966K
Beneficiaries
13
66 claims
Per beneficiary
$74,314
$4,810.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $289,558 |
| 2024 | $966,087 |
Part B: Tecvayli (Teclistamab-Cqyv) · HCPCS J9380
2024 spending
$200M
Beneficiaries
1,549
19,555 claims
Per beneficiary
$129,048
2024 ASP limit $31.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $88,245,815 |
| 2024 | $199,895,746 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Costa LJ, Bahlis NJ, Perrot A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, et al. · N Engl J Med 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cohen YC, Magen H, Gatt M, et al. · N Engl J Med 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Touzeau C, Krishnan AY, Moreau P, et al. · Blood 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Touzeau C, Mina R, Quach H, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Teclistamab, a B-cell maturation antigenߘ×ߘCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ, Garfall AL, van de Donk NWCJ, et al. · Lancet 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.